Janux Therapeutics, Inc. Lease Obligation Incurred
Janux Therapeutics, Inc. (JANX) reported Lease Obligation Incurred of $943.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2026-02-26
- Janux Therapeutics, Inc. lease obligation incurred for the quarter ending 2025-12-31 was $0.00.
- Janux Therapeutics, Inc. lease obligation incurred for the quarter ending 2024-12-31 was $0.00.
- Janux Therapeutics, Inc. lease obligation incurred for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Janux Therapeutics, Inc. lease obligation incurred for the quarter ending 2023-09-30 was $0.00.
- Janux Therapeutics, Inc. lease obligation incurred for fiscal 2025 was $943.00K.
- Janux Therapeutics, Inc. lease obligation incurred for fiscal 2024 was $0.00.
- Janux Therapeutics, Inc. lease obligation incurred for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Janux Therapeutics, Inc. lease obligation incurred for fiscal 2022 was $23.42M, a 9049.22% increase from fiscal 2021.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $943.00K 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $943.00K 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $344.00K derived: sum of 2 quarters · filed 2025-02-27 | $23.42M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $23.08M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $23.08M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $256.00K derived: sum of 2 quarters · filed 2023-03-10 | $256.00K 10-K · filed 2023-03-10 | |
| 2021-09-30 | $256.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $256.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |